Literature DB >> 18549935

Prognostic significance of pleural fluid data in patients with malignant effusion.

Silvia Bielsa1, Antonieta Salud, Montserrat Martínez, Aureli Esquerda, Antonio Martín, Francisco Rodríguez-Panadero, José M Porcel.   

Abstract

BACKGROUND: To determine the effects of the biochemical and cytological properties of the pleural fluid (PF) on the survival of patients with malignant pleural effusion (MPE).
METHODS: A retrospective study of 284 patients with MPE was performed, which measured overall survival, survival of patients with different types of primary tumors, and survival as a function of PF biochemical variables transformed into quartiles.
RESULTS: Median overall survival of MPE patients was 5.4 months following diagnosis. Survival varied significantly depending on the type of the primary tumor: 17.4 months for mesothelioma, 13.2 months for breast cancer, 7 months for lymphoma and 2.6 months for lung cancer. A multivariate analysis of PF biochemical parameters showed that survival was lower as the concentration of lactate dehydrogenase (LDH) increased (11.3 months if LDH was between 140 U/L and 358 U/L vs 2.8 months if LDH was between 1027 U/L and 10,110 U/L) or the concentration of pleural proteins decreased (9.4 months if proteins were between 4.92 g/dL and 7.94 g/dL vs 2.2 months if proteins were between 0.97 g/dL and 3.85 g/dL). We also found that when mesotheliomas were excluded from the analysis, survival was lower in patients with a PF pH lower than 7.3 (2.4 months vs 6.8 months, p=0.03).
CONCLUSIONS: Tumor type as well as some biochemical features of the pleural fluid, such as pH and concentrations of proteins and LDH, influence survival in patients with MPE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18549935     DOI: 10.1016/j.ejim.2007.09.014

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  34 in total

1.  A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

Authors:  Katherina-Bernadette Sreter; Marko Jakopovic; Zoran Janevski; Miroslav Samarzija; Paul Zarogoulidis; Ioannis Kioumis; Nikolaos Mparmpetakis; Athanasia Pataka; Konstantinos Zarogoulidis; Theodora Tsiouda; Christoforos Kosmidis; Sofia Mpaka; Haidong Huang; Wolfgang Hohenforst-Schmidt; Charalampos Charalampidis; Nikolaos Machairiotis; Bojan Zaric; Aleksandar Milovancev
Journal:  Ann Transl Med       Date:  2016-05

2.  Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion.

Authors:  Fan Zhang; Lijuan Hu; Junjun Wang; Jian Chen; Jie Chen; Yumin Wang
Journal:  J Clin Lab Anal       Date:  2016-12-15       Impact factor: 2.352

3.  Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.

Authors:  Da-Wei Wu; Wei-An Chang; Kuan-Ting Liu; Meng-Chi Yen; Po-Lin Kuo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

4.  Tumor type influences the effectiveness of pleurodesis in malignant effusions.

Authors:  Silvia Bielsa; Paula Hernández; Francisco Rodriguez-Panadero; Teresa Taberner; Antonieta Salud; José M Porcel
Journal:  Lung       Date:  2011-02-18       Impact factor: 2.584

Review 5.  Diagnosis and management of malignant pleural effusions: state of the art in 2017.

Authors:  Neeraj R Desai; Hans J Lee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.

Authors:  Ianko D Iankov; Pavlos Msaouel; Cory Allen; Mark J Federspiel; Peggy A Bulur; Allan B Dietz; Dennis Gastineau; Yasuhiro Ikeda; James N Ingle; Stephen J Russell; Evanthia Galanis
Journal:  Breast Cancer Res Treat       Date:  2009-11-06       Impact factor: 4.872

7.  Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma.

Authors:  Maribel Botana-Rial; Loretta De Chiara; Diana Valverde; Virginia Leiro-Fernández; Cristina Represas-Represas; Victor Del Campo-Pérez; Alberto Fernández-Villar
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

Review 8.  Interventions for the management of malignant pleural effusions: a network meta-analysis.

Authors:  Amelia O Clive; Hayley E Jones; Rahul Bhatnagar; Nancy J Preston; Nick Maskell
Journal:  Cochrane Database Syst Rev       Date:  2016-05-08

9.  Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer.

Authors:  Tingting Wang; Mingming Lv; Sunan Shen; Sheng Zhou; Ping Wang; Yueqiu Chen; Baorui Liu; Like Yu; Yayi Hou
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

10.  Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis.

Authors:  Sofia Molina; Gabriela Martinez-Zayas; Paula V Sainz; Cheuk H Leung; Liang Li; Horiana B Grosu; Roberto Adachi; David E Ost
Journal:  Chest       Date:  2021-05-11       Impact factor: 10.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.